PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 25 October 2022, 07:00 am CET alfapump achieves pre-specified primary effectiveness endpoints with statistical significance at six months post-implantation: 100% median per-patient reduction in therapeutic paracentesis (TP) post- vs pre-implantation (p<0.001) 77% of patients with at least 50% reduction in number of TP post- vs pre-implantation (p<0.001)...Read More
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 8 September 2022, 07:00 CET alfapump® – strong interim data / on track to report primary endpoint data of North American pivotal POSEIDON study in Q4 2022 DSR® – clinical evidence of disease-modifying heart failure drug therapy / preparations ongoing to start US phase 1b/2a MOJAVE study...Read More
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 20 July 2022, 07:00 CET Company’s cash runway extended into Q3 2023 Ghent, Belgium – 20 July 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces...Read More
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 19 July 2022, 07:00 am CEsT DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart...Read More
PRESS RELEASE REGULATED INFORMATION 27 May 2022, 06:00 pm CEST Ghent, Belgium – 27 May 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that all proposed resolutions submitted to the...Read More
PRESS RELEASE REGULATED INFORMATION 27 April 2022, 07:00 am CEST Publication of Annual Report 2021 Ghent, Belgium – 27 April 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today invites the holders...Read More
PRESS RELEASE REGULATED INFORMATION 12 April 2022, 07:00 CET alfapump® in liver disease Positive results from second interim analysis of POSEIDON pivotal study; encouraging survival data at 12 months vs. published literature Patient enrolment and implants completed; primary endpoint on track for Q4 2022 FDA regulatory submission planned for mid-2023 DSR® in heart failure...Read More
PRESS RELEASE Regulated information 28 March 2022, 6 p.m. CET Ghent, Belgium – 28 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces today that it received a transparency notification from...Read More
PRESS RELEASE Regulated information 18 March 2022, 6 p.m. CET Ghent, Belgium – 18 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces today that it received transparency notifications from the...Read More
PRESS RELEASE REGULATED INFORMATION 10 March 2022, 18:00 CET Ghent, Belgium, 10 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces that in the context of the capital increase that was...Read More
